Active — Not RecruitingNot Applicable

Pediatric HIV Disclosure Benefits Study (PhD-BS) - Sankofa 2

Ghana747 participantsStarted 2021-06-15

Plain-language summary

The purpose of this study is to conduct a pragmatic, stepped wedge cluster randomized trial in 12 HIV pediatric clinics in Ghana to determine effectiveness, health benefits, cost and implementation to inform scale-up and sustainability of pediatric disclosure.

Who can participate

Age range7 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HIV infected children * Children between the ages of 7-18 who do not know their HIV diagnosis (based on caregiver account and medical records confirmation) and their caregivers will be eligible to participate in the study Exclusion Criteria: * HIV-infected children less than 7 years * HIV-infected children with congenital or developmental disorders * HIV-infected children with comorbidities such as sickle cell disease or diabetes that require frequent clinic visits or hospitalizations * Children with AIDS-defining illness or end stage AIDS.

What they're measuring

HIV disclosure rate

Timeframe: 1 year after intervention

Trial details

NCT IDNCT04791865

SponsorBoston University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More HIV trials